Jeffrey Cummings, AAN 2021: Phase 2b Study of BAN2401 in subjects with Early Alzheimer’s Disease

touchNEUROLOGY caught up with Jeffrey Cummings (University of Nevada, Las Vegas, NV, USA) one of our valued Editorial Board Members, to discuss the open-label extension of the Phase 2b Study (BAN2401-G000-201) in subjects with early Alzheimer’s Disease.

The abstract entitled: ‘Preliminary Analysis Of BAN2401 Effects On Brain Amyloid And ARIA-E Findings Over 12 Months Of Treatment In The Open-Label Extension Of The Phase 2b Study BAN2401-G000-201 In Subjects With Early Alzheimer’s Disease’ was presented in relation to this interview, at the American Academy of Neurology Virtual Annual Meeting 2021.

Questions:

1. Could you tell us a little about the aims and design of the BAN2401-G000-201 study? (0:18)
2. What were the findings of the preliminary analysis of the effects of BAN2401 on brain amyloid and Amyloid Related Imaging Abnormalities (AIRA)-E? (2:42)
3. At what stage is BAN2401 likely to be employed in clinical use? (3:57)
4. What will be the next steps in the clinical development of BAN2401? (5:04)

Disclosures: TBC

Support: Interview and filming supported by Touch Medical Media.

Filmed as a highlight of AAN Annual Virtual Meeting 2021.